DMD and Duchenne muscular dystrophy: The FDA has approved AONs, such as Eteplirsen (phosphorodiamidate morpholino oligomer targeting exon 51 of the dystrophin gene) and Golodirsen (similarly engineered for exon 53), as first-in-class splice-modulating agents, authorized under accelerated approval for frame-restoring dystrophin rescue in DMD patients with mutation-defined exon skipping eligibility [138,139].